CHICAGO, October 18, 2004 (LifeSiteNews.com) – The US Food and Drug Administration has re-opened the case to approve non-prescription sales of the abortifacient morning-after pill to girls 16 years of age or older, after a new proposal was submitted by the manufacturer, Barr pharmaceuticals. An earlier proposal to sell the drug without a prescription was rejected by the FDA in May; subsequently, Barr re-applied, because the earlier FDA decision left a loophole saying they might reconsider if Barr could show some way of guaranteeing that the drug will only be sold without prescription to girls and women over 16.
Allowing sales without a prescription, besides encouraging promiscuity, will also raise the rates of sexually transmitted diseases and have other consequences, according to gynecologist Dr. Gene Rudd. “They’re not going to get their Pap smears; they’re not going to get screened for sexually transmitted disease,” he said, according to an Associated Press report.
The FDA is expected to release a decision on the matter by early 2005. Tv